Company ProfilePremium

MEDIBANK PRIVATE LTD

Company Profile Analysis

Ticker: MPL.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
MEDIBANK PRIVATE LTD - Company showcase

Year Founded & Workforce

1976

MEDIBANK PRIVATE LTD logo

MEDIBANK PRIVATE LTD Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

MEDIBANK PRIVATE LTD Overview

Medibank is Australia's largest listed private health insurer and is building a broader health-services business. It holds about 26.3% of the resident private health insurance (PHI) market through the Medibank and ahm brands (APRA, March 2026). It also insures about 346,000 non-resident policy units (students, workers, visitors). It is the preferred provider of overseas student health cover at nearly half of Australian universities (FY2024 release).

The group positions itself as a "health company". Its Medibank Health segment (wellbeing, primary care, and community and acute care) is run through Amplar Health. This segment earned A$100.7m in FY2026, up 31.3%. It now includes 168 owned or majority-owned GP clinics following the A$163.5m Better Medical acquisition. FY2026 underlying NPAT was A$636.8m on group revenue of A$9.1bn, with a fully franked dividend of 19.2c.

Management's 2030 aspirations are:

  • Medibank Health profit of more than A$200m.

  • Resident market share above 26.8%.

  • Engagement with about 10 million people.

The 2022 cybercrime event remains the main legal overhang.


What Medibank does. Medibank underwrites and distributes private health insurance:

Resident PHI: hospital and extras cover under the Medibank (premium/mainstream) and ahm (value) brands.

Non-resident PHI: Overseas Student Health Cover, Overseas Visitor and worker covers.

Through Medibank Health it also delivers health services:

Wellbeing: Live Better rewards, corporate health, and "financial wellbeing" distribution of travel, pet, life, income-protection, car and home insurance.

Primary care: Myhealth (92.7% owned), Better Medical (100%), Amplar Health virtual care and online doctor.

Community and acute care: Amplar Health home hospital and transition care, plus joint-venture short-stay hospitals and mental-health facilities.

Company's own framing (FY2026 Investor Presentation, paraphrased).

  • Purpose: "Better Health for Better Lives".

  • Vision: to create the best health and wellbeing for Australia.

  • Five operating segments: resident health insurance, non-resident health insurance, wellbeing, primary care, and community and acute care.

  • Differentiation: supporting whole-of-health needs, deepening customer relationships, driving change in the health system, and giving customers more value, choice and control.

Revenue model.

The segment figures above add to slightly more than the A$9,115.2m group revenue from external customers (they include some intra-group revenue). Group revenue from external customers is the reported total.

Value-chain position. Medibank is the payer at the centre of the private health system. It collects premiums and pays benefits to private hospitals (64% of resident hospital claims), medical specialists (14%), prostheses suppliers (12%) and public hospitals (7%). Extras benefits go to dental (55% of extras), optical (16%), physiotherapy, chiropractic and others (FY2026 presentation). It is increasingly vertically integrating into care delivery (GP clinics, home hospital, short-stay JV hospitals) to manage claims costs and engage customers.

Customers and end-markets.

  • Australian households (singles, couples, families); 2,025,300 resident policyholders and 3.09m hospital lives.

  • Corporate clients (record corporate policyholder growth in FY2026).

  • International students, workers and visitors.

  • Public payers: state health departments buying home hospital and transition care, and Medicare via GP billing.

Independent characterisation. Medibank is a capital-light, cash-generative, defensive franchise in a regulated oligopoly. Its insurance economics rest on a broadly stable resident gross margin of about 16–17% and an industry-low management expense ratio of about 8%. Investment income adds roughly a fifth of pre-tax profit. The strategic bet is that owning primary care and out-of-hospital care will lower claims inflation, raise retention and create an earnings stream outside regulated premiums. That stream is about 12% of group operating profit today. The main constraint is regulatory: premium rises need ministerial approval, and the A$250m APRA capital overlay remains until cyber remediation is complete.

Strategy

Strategic pillars (FY2026 presentation; Medibank's own labels).

  1. Deliver leading experiences. Increase advocacy and trust; simplify customer experiences; reinvent ways of working with AI and autonomous teams; lead the health transition.

  2. Differentiate our insurance business. Disciplined resident growth in priority segments (families, those new to the industry, corporate, direct channels); return to non-resident growth; integrated PHI and health propositions.

  3. Expand in health. Increase wellbeing engagement; accelerate GP-led primary care; expand home-based and transitional care.

  4. Continue to strengthen our foundations. Risk culture ("Risk Fit" framework), technology simplification, automation and AI, productivity.

2030 aspirations and milestones.

The strategy also targets incremental PHI value equal to about 5% of PHI operating profit between FY2025 and FY2030 through health engagement.

Initiatives in the last 24 months.

  • Better Medical acquisition (A$163.5m).

  • Online Doctor expanded to all Medibank customers.

  • Recover Boost launched.

  • "Customer first" program.

  • AI scaling across the business.

  • Risk Fit framework.

  • A$50m five-year mental-health commitment (A$11.5m in FY2026).

  • More than A$40m provided to private hospitals for sustainability and innovation (FY2026).

  • Corporate health platform investment (about A$10m additional Medibank Health spend).

  • About A$10m a year of productivity savings: A$132.4m cumulative in under a decade.

  • Medibank Group brand launch (1 Oct 2026).

  • First ASRS-aligned Sustainability Report (Sep 2026).

FY2027 guidance (20 Aug 2026).

  • Grow resident market share in a disciplined way, including improved Medibank-brand momentum.

  • Resident PHI gross margin broadly consistent with FY2026, subject to the April 2027 premium round.

  • Solid non-resident gross profit growth.

  • Medibank Health segment profit growth of about 25%, including a full year of Better Medical.

  • About A$10m of further productivity savings.

  • HI expense growth of about 5.4% (per Rivkin summary).

  • Cyber costs below A$20m.

  • Dividend payout range of 75–85% of underlying NPAT.

Products & Services

A. Health Insurance — resident

B. Health Insurance — non-resident

C. Medibank Health — Wellbeing

D. Medibank Health — Primary care (Amplar Health network)

E. Medibank Health — Community and acute care

Pricing: PHI premiums are publicly listed by product and state but not summarised in filings. Medibank's average resident premium increase was 3.48% in FY2025 and 4.27% in FY2026 (FY2026 presentation). The 1 April 2026 increase averaged 5.1% (CHOICE).

Product Portfolio

Product / brandDescriptionTarget customerNotes

Medibank (brand)

Full-service insurer with hospital tiers (Basic, Bronze, Silver, Gold under federal product reforms) and extras

Mainstream and premium households, families, corporates

1,448,100 policyholders at FY2026 (+0.6%); acquisition rate 9.9%, lapse 9.3%

ahm (brand)

Value-oriented, digital-first insurer

Price-sensitive and younger customers

577,200 policyholders (+2.4%); direct joins rose to 51% of ahm joins in FY2026

Members' Choice / Members' Choice Advantage networks

Extras provider networks (dental, optical, physio, chiro, podiatry, acupuncture, remedial massage) offering lower out-of-pocket costs

All Medibank extras customers

About A$243m in customer savings in FY2026 (+6%); about 4,000 provider locations

No-gap hospital program

Medibank-funded procedures with no out-of-pocket costs, including joint replacements

Hospital customers

1 in 5 Medibank-funded joint replacements in Melbourne and Sydney delivered in a no-gap hospital

Recover Boost

Recovery-support benefit launched in FY2026

Medibank and ahm customers

Launched FY2026

Live Better (integrated with cover)

Rewards for healthy behaviour, redeemable for partner products or premium savings

Medibank customers

1,039k members; A$48.6m in rewards claimed FY2026 (+48%)

Corporate health insurance

Group schemes for employers

Corporates

Record corporate policyholder growth in FY2026

ProductDescriptionTargetNotes

Overseas Student Health Cover (OSHC)

Visa-compliant cover

International students

Preferred provider at nearly half of Australian universities (FY2024)

Overseas Workers / Visitors cover

Visa-compliant cover

Skilled and graduate workers, visitors

Worker policy units grew 23% vs 11% growth in skilled and graduate visa grants (FY2026); new visitor products launched

Lifecycle conversion

Moving students to worker cover and then to resident PHI

Non-residents becoming residents

Resident joins from non-resident rose to 8.4% (FY2026) from 7.5%

OfferingDescriptionMetric (FY2026)

Live Better

Digital rewards and challenges program

1,039k participants; FY2028 milestone above 1.2m

Everyday prevention programs

Self-paced digital prevention and recovery programs

334k enrolments; FY2028 milestone above 380k

Corporate Health

Workforce mental health and wellbeing services

15% of accounts engaged; FY2028 milestone above 20%

Financial wellbeing

Distribution of travel, pet, life, income-protection, car and home insurance (commission-based)

356k policies (+4.7%); FY2028 milestone above 440k

Mental health commitment

Five-year A$50m program

A$11.5m invested in FY2026

OfferingDescriptionMetric

Myhealth Medical Group (92.7%)

GP-led multidisciplinary clinics across eastern Australia

About 105 clinics (Nov 2025 release)

Better Medical (100%)

61 GP and medical clinics in VIC, QLD, SA and TAS; about 800 clinicians

Acquired for A$163.5m; contributed A$6.2m in its first six months

Amplar Health Online Doctor / virtual care

Telehealth GP, 24/7 nursing, health concierge, mental-health triage

Online doctor expanded to all Medibank customers; virtual consults 21.7% of GP consults

Proactive Primary Care Program

GP-identified at-risk patients with care plans and follow-up

Clinician-guided prevention services 36k; FY2028 milestone 45k

GP consultations

Total across the network

4.134m (+26.7%); FY2028 milestone 7m

OfferingDescriptionMetric

Amplar Health Home Hospital (100% owned)

Hospital-in-the-home care for private and public patients

27.4k acute home health admissions (+13.7%); about 194k bed days saved

Transition Care Service

Joint service with SA Health / Central Adelaide Local Health Network

Capacity expanded in FY2026

Community care

Nursing, allied health and personal care at home

106.2k visits; FY2028 milestone 155k

JV short-stay hospitals

East Sydney Day Hospital (49%), Adeney Private Hospital, Melbourne (49%), Western Adelaide Hospital (49%), SydOrtho / MQ Health Orthopaedic Institute (50%)

JV losses A$6.6m; break-even targeted in FY2028

Integrated Mental Health (50%)

Mental-health hospitals plus out-of-hospital support

A$27.4m invested to June 2026

Financial Narrative

Basis: FY2022 is pre-AASB 17 as originally reported. FY2023 is restated under AASB 17 (original FY2023 values are given in notes). FY2024–FY2026 are as reported. Sources: FY2022 Media Release; FY2023 Appendix 4E and Media Release; FY2024 Media Release; FY2026 Investor Presentation (FY2025–FY2026).

Income statement

Notes: FY2022 PBT not captured (shown as 0): - FY2022 EPS figures are computed from NPAT and about 2,754m shares; the others are reported.

  • FY2023 as originally reported: revenue A$7,355.3m, statutory NPAT A$511.1m, underlying NPAT A$499.6m.

  • The FY2023 restated statutory NPAT (A$308.6m) is depressed by a A$290.1m pre-tax COVID-19 reserve movement. COVID-reserve movements were A$110.8m in FY2024, A$182.8m in FY2025 and nil in FY2026.

  • FY2022 DPS = 6.1c interim + 7.3c final (InvestSMART dividend history), consistent with the stated 9.0% FY2023 increase.

Margins.

Computed from the table above. FY2023 HI gross margin is implied (16.5% less 40bps) and FY2022 is n.d. "Gross profit" and "EBITDA" are not insurance-standard measures. The insurance gross profit equivalent is HI gross profit: A$1,307.2m in FY2024, A$1,396.4m in FY2025 and A$1,460.0m in FY2026. Group EBITDA is n.d.

Growth.

  • Revenue CAGR FY2023–FY2026 on the AASB 17 basis: 5.3% a year (computed).

  • Underlying NPAT CAGR FY2022–FY2026: 10.0% a year (computed; spans the basis change).

  • Operating profit CAGR FY2022–FY2026: 8.2% a year.

Balance sheet and capital

Zeros mark values not captured in the sources reviewed: Total assets: n.d. at group level. APRA reported A$3.91bn total assets and A$1.69bn net assets for the Medibank health benefits fund entity in 2024–25.

Goodwill and intangibles: "intangible and other adjustments" deducted from eligible capital were A$465.9m (FY2025) and A$647.6m (FY2026), including Better Medical goodwill and software.

Debt: no bank borrowings or bonds disclosed. Lease liabilities exist (AASB 16 interest A$17.6m in FY2026 vs A$12.0m in FY2025). Management says it "can raise Tier 2 debt" if needed.

Net debt: net cash; precise figure n.d.

Working capital: not meaningful for an insurer.

Cash flow and capital returns

Not captured: operating cash flow, capex (D&A in HI was A$49.5m in FY2026), free cash flow and dividends paid in cash.

M&A program: A$218m invested in M&A over FY2024–FY2026 against a A$150–250m target (Better Medical release).

Buybacks: none in FY2022–FY2026. The board says it will consider capital management if suitable M&A does not eventuate.

Ratios

FY2025 ROE is n.d. because FY2024 equity was not captured. Current ratio, debt/equity, net debt/EBITDA, interest coverage and cash conversion cycle are not meaningful: Medibank is a debt-free insurer. ROA and ROIC are n.d. without group total assets.

Commentary

Growth: Group revenue has grown 4.7–5.9% a year since FY2024. Drivers are premium indexation (3.5–4.3% average resident increases), modest policy-unit growth (1–2%) and the expanding health-services business (+30.8% in FY2026, partly from Better Medical and full ownership of Amplar Health Home Hospital).

Insurance margins: The resident gross margin was 16.3% in FY2026, still below the pre-COVID FY2019 level of 17.1%. FY2026 included a A$74.8m non-recurring COVID utilisation benefit (about 150bps on hospital claims), which will not recur in FY2027. Management nonetheless guides to a broadly stable resident gross margin.

Investment income: Investment income turned from a A$24.8m loss in FY2022 to A$207.8m in FY2025 as cash rates rose. It fell to A$178.9m in FY2026 as the RBA eased and cash holdings shrank. Each 25bps on the cash rate is worth about A$6.4m.

Statutory vs underlying: The large gap in FY2023–FY2025 reflects COVID-19 reserve accounting, now finalised. FY2026 statutory and underlying NPAT have converged (A$638.7m vs A$636.8m).

Cyber costs: Cyber costs remain non-recurring at A$35–46m a year. FY2027 is guided below A$20m, excluding any penalties or settlements.

Capital: The required capital ratio (13.3%) sits above the 10–12% target only because of the A$250m APRA overlay. If the overlay is removed, about A$250m of capital would be released.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment

SegmentFY2022FY2023FY2024FY2025FY2026

Health Insurance operating profit (AUD Mn)

592.6651.3692.3741.5769.8

Medibank Health segment profit (AUD Mn)

044.260.476.7100.7

Corporate overheads (AUD Mn)

0-47.1-52.9-55.8-57.0

Group operating profit (AUD Mn)

594.1648.4699.8762.4813.5

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Premium revenue (AUD Mn)

7,903.08,211.08,585.1

Resident premium revenue (AUD Mn)

07,908.88,267.9

Non-resident premium revenue (AUD Mn)

0302.2317.2

Gross profit (AUD Mn)

1,307.21,396.41,460.0

Gross margin (%)

16.517.017.0

Resident gross margin (%)

15.916.216.3

Non-resident gross margin (%)

34.236.934.8

Management expenses (AUD Mn)

614.9654.9690.2

Expense ratio (%)

7.88.08.0

Operating margin (%)

8.89.09.0

Revenue by Segment and Segment Margins & Growth (%) (FY2025–FY2026)

Sub-segmentFY2025FY2026

Wellbeing revenue (AUD Mn)

144.9175.5

Primary care revenue (AUD Mn)

244.3316.5

Community and acute revenue (AUD Mn)

96.0142.8

Total Medibank Health revenue (AUD Mn)

485.2634.8

Wellbeing operating profit (AUD Mn)

56.362.8

Primary care operating profit (AUD Mn)

29.138.8

Community and acute operating profit (AUD Mn)

-0.110.1

Share of loss from JV investments (AUD Mn)

-7.5-6.6

Medibank Health operating margin (%)

17.416.9

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2024FY2025FY2026

HI premium revenue growth YoY (%)

4.03.94.6

Medibank Health revenue growth YoY (%)

0030.8

Medibank Health share of segment operating profit (%)

8.09.411.6

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Group revenue from external customers (AUD Mn)

7,128.57,807.08,175.88,604.09,115.2

Group operating profit (AUD Mn)

594.1648.4699.8762.4813.5

Net investment income (AUD Mn)

-24.8138.6182.2207.8178.9

Cybercrime costs (AUD Mn)

0-46.4-39.8-39.7-34.9

Profit before tax (AUD Mn)

0437.9711.7728.8927.9

Statutory NPAT attributable (AUD Mn)

393.9308.6492.5500.8638.7

Underlying NPAT (AUD Mn)

435.1500.1570.4618.7636.8

Statutory EPS (cents)

14.311.217.918.223.2

Underlying EPS (cents)

15.818.220.722.523.1

Ordinary DPS, fully franked (cents)

13.414.616.618.019.2

Payout ratio of underlying NPAT (%)

84.880.580.180.183.0

Margin

MarginFY2022FY2023FY2024FY2025FY2026

Group operating margin (%)

8.38.38.68.98.9

Underlying net margin (%)

6.16.47.07.27.0

Statutory net margin (%)

5.54.06.05.87.0

Health Insurance gross margin (%)

016.116.517.017.0

Dividends & Capital Returns and Margin Analysis (%)

MetricFY2024FY2025FY2026

Total equity (AUD Mn)

02,336.12,410.7

Capital employed after unpaid dividend (AUD Mn)

02,055.22,110.5

Health Insurance capital employed (AUD Mn)

01,332.21,323.8

Medibank Health capital employed (AUD Mn)

0412.0559.8

Unallocated capital (AUD Mn)

186.2251.9182.9

Health Insurance required capital (AUD Mn)

1,161.61,195.81,197.4

Required capital ratio (%)

14.114.013.3

PCA coverage ratio (x)

1.81.81.9

Total investment portfolio, spot (AUD Mn)

003,352.6

Cash and cash equivalents (AUD Mn)

00570.4

Per-Share Data and Dividends & Capital Returns

MetricFY2024FY2025FY2026

Ordinary dividends determined (cents per share)

16.618.019.2

Final dividend determined but unpaid (AUD Mn)

0280.9300.2

M&A investment, Better Medical (AUD Mn)

00163.5

Myhealth step-up (AUD Mn)

52.007.9

Margin Analysis (%)

RatioFY2025FY2026

Underlying ROE on average equity (%)

026.8

Statutory ROE on average equity (%)

026.9

Effective tax rate (%)

30.130.3

Underlying spread to RBA cash rate (%)

1.661.77

Fund portfolio return, reported (%)

6.385.71

Business Lines

LineFY2025FY2026

Resident PHI premium (AUD Mn)

7,908.88,267.9

Non-resident PHI premium (AUD Mn)

302.2317.2

Medibank Health revenue (AUD Mn)

485.2634.8

Resident PHI growth YoY (%)

04.5

Non-resident PHI growth YoY (%)

05.0

Medibank Health growth YoY (%)

030.8

Point Details

PointPrice (AUD)

Jun 2024 (OAIC filing day)

3.70

Jan 2025

3.79

28 Aug 2025 (FY2025 result)

5.15

17 Feb 2026

4.52

20 Mar 2026

4.21

5 May 2026

4.73

Post-FY2026 result (latest snapshot)

5.28

Valuation Multiples

MultipleMedibankComment

P/E on FY2026 underlying EPS 23.1c (x)

22.9

Computed

P/E on statutory EPS 23.2c (x)

22.8

Computed

Dividend yield, cash (%)

3.6

19.2c / A$5.28; about 5.2% grossed-up for franking

P/B on equity A$2,410.7m (x)

6.0

Computed

Peer nib (NHF)

—

Not captured

Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Interim DPS (cents)

6.16.37.27.88.3

Final DPS (cents)

7.38.39.410.210.9

Total DPS (cents)

13.414.616.618.019.2

Analyst Conclusions

Management FY2027 guidance.

  • Disciplined resident market-share growth with improved Medibank-brand volume.

  • Resident gross margin broadly consistent with FY2026, absorbing the A$74.8m benefit unwind.

  • Solid non-resident gross profit growth.

  • Medibank Health profit growth of about 25%.

  • About A$10m of productivity savings.

  • Cyber costs below A$20m.

  • An ongoing M&A pipeline in primary care and wellbeing.

Consensus. Pre-result consensus assumed about 1.3% FY2027 policyholder growth (Ord Minnett). Detailed FY2027 EPS consensus is n.d.

Bull case

  1. Earnings mix shift. Medibank Health growing about 25% in FY2027 towards more than A$200m by FY2030 would lift its share of group operating profit from about 12% to around 20%, supporting a higher multiple.

  2. Capital release. Removal of the A$250m APRA overlay, plus PCA coverage of 1.9x and no debt, creates room for M&A or special returns.

  3. Defensive compounding. Operating profit has grown each year since FY2022 (about 8% CAGR), with a stable 17% HI gross margin and a franked yield of about 3.6%.

Bear case

  1. Competitive drift. Share fell to 26.3%, 2H26 growth was only +0.2% and lapses spiked. Price rises above the industry (5.1% vs 4.41%) risk further switching.

  2. Claims normalisation. The non-recurring A$74.8m benefit plus higher hospital indexation could squeeze FY2027 resident margins if the April 2027 premium round is constrained.

  3. Litigation tail. The OAIC penalty and class-action damages, now with the Deloitte reports in evidence, are unprovisioned and could be material against about A$637m of annual NPAT.

Catalysts and monitorables (next 12 months)

  • 18 Nov 2026 AGM: remuneration vote; director elections.

  • APRA quarterly market-share data.

  • 1H FY2027 result (Feb 2027): resident growth, Better Medical integration, claims trends.

  • April 2027 premium round approval.

  • Rulings or settlement discussions in the OAIC and class-action proceedings.

  • Any APRA decision on the A$250m overlay.

  • RBA cash-rate path.

  • Further primary-care or wellbeing acquisitions.

  • Non-resident student-visa settings.

Analyst verdict. Medibank enters its 51st year as a high-quality, defensive franchise in the middle of a long strategic transition. The insurance core is efficient and well capitalised. An 8.0% expense ratio, a 17.0% gross margin, PCA coverage of 1.9x and no debt let it pay out 83% of underlying earnings while still funding acquisitions such as the A$163.5m Better Medical deal.

FY2026 showed both the strengths and the limits of the model. Group operating profit rose 6.7% and Medibank Health grew 31%. Underlying NPAT rose only 2.9%, however, because lower cash rates cut investment income. Policyholder growth also almost stalled in the second half, when competitors and aggregators pushed hard. Medibank's market share is drifting below its own scorecard levels. Its 2030 target of more than 26.8% now looks ambitious unless the Medibank brand's improved acquisition rate holds.

The equity story increasingly rests on Medibank Health. It must almost double profit by FY2030, integrate 168 clinics, and bring the JV hospitals to break-even, while also showing that owning care lowers claims costs. The early evidence is encouraging: 27k home-hospital admissions, community care in profit and a growing Live Better membership. The segment is still only about 12% of operating profit.

The biggest swing factor is legal, not operational. The OAIC penalty and the consumer and shareholder class actions remain unprovisioned, and the Deloitte reports must now be produced. At about 23x underlying earnings and a 3.6% franked yield, the stock prices in much of the defensive quality. We see Medibank as a core holding with balanced risk and reward. The upside depends on capital release when the APRA overlay ends and on Medibank Health's delivery. The downside is limited by the franchise but exposed to litigation outcomes and share loss.


Sources consulted

  • Medibank FY2026 Results Investor Presentation (20 Aug 2026), medibank.com.au and ASX

  • Medibank FY2026 Results Media Release and Appendix 4E (20 Aug 2026)

  • Medibank Annual Report 2026 release and ASX cover letter (16 Sep 2026); newsroom release on Annual Report 2026 and brand launch

  • Medibank HY2026 results media release and Appendix 4D (19 Feb 2026); InvestSMART summaries

  • Medibank FY2025 results media release (28 Aug 2025); Livewire Markets; InvestSMART summary

  • Medibank FY2024 results media release (22 Aug 2024); HY2024 release (22 Feb 2024)

  • Medibank FY2023 Appendix 4E and media release (24 Aug 2023); FY2022 media release (18 Aug 2022); FY2021 media release (25 Aug 2021)

  • Medibank newsroom: Better Medical agreement and completion; Jay Weatherill retirement; board renewal (5 Sep 2025); FY2026 key dates; business updates (May 2025, 5 May 2026); consumer class action update (20 Mar 2026); 2021 board retirements; CEO appointment

  • Medibank board page (medibank.com.au/about/company/board)

  • Rivkin (20 Aug 2026), Ord Minnett (31 Aug 2026), Motley Fool, AAP (via Newcastle Herald and others) coverage of FY2026

  • OAIC proceedings coverage: Government News, The New Daily, Capital Brief, ACS Information Age; class-action coverage: Insurance Business, Lawyerly, Reuters/Teiss

  • APRA Quarterly Private Health Insurance Statistics, March 2026; Insurance Business on APRA 2024–25 insurer statistics; CHOICE market-share and premium analysis (2025–2026)

  • InvestSMART and Market Index price, dividend and director-trade pages; Medical Republic and AusDoc on Better Medical

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedOther roles / background

Mike Wilkins AO (BCom, MBA, FAICD, FCA)

Independent Chair; Chair, Nomination Committee

Director May 2017; Chair 1 Oct 2020

Former QBE Chair (to May 2026); former IAG MD & CEO; former AMP Executive Chair; director, Scentre Group

David Koczkar

Managing Director & CEO

CEO 17 May 2021

Previously Medibank executive (Chief Customer Officer / Group Executive roles)

Dr Tracey Batten

Independent NED; Chair, People & Remuneration Committee

Aug 2017

Chair, Accident Compensation Corporation (NZ)

Gerard Dalbosco

Independent NED; Chair, Audit Committee

May 2021

Director, Mercy Health & Aged Care; Committee for Melbourne

Peter Everingham

Independent NED; Chair, Investment & Capital Committee

Mar 2022

—

Kathryn Fagg AO

Independent NED; Chair, Risk Management Committee

Mar 2022

Chair of Watertrust Australia, Parks Victoria, Melbourne Recital Centre, Breast Cancer Network Australia

Jacqueline (Jacquie) Hey

Independent NED

Nov 2025

Former Chair, Bendigo and Adelaide Bank

Dr Lisa McIntyre

Independent NED

Nov 2025

Chair, Women for Change Committee of the LBW Trust

Executive Leadership Team

NameRole

David Koczkar

Chief Executive Officer

Mark Rogers

Group Lead – Chief Financial Officer & Group Strategy

Robert Read

Chief Executive, Amplar Health

Milosh Milisavljevic

Chief Customer Officer (per FY2024 coverage)

Board & Management Changes

DateDirectorSharesPrice (AUD)Value (AUD)

23 Feb 2026

Lisa McIntyre

22,3704.48100,217

27 Feb 2026

Peter Everingham

25,0004.41110,250

2 Mar 2026

Jacqueline Hey

11,4484.4250,600

Competitive Landscape

Market Share by Competitor

CompetitorMarket share (%)OwnershipPositioning

Medibank (incl. ahm)

26.5 (Medibank-reported APRA figure for Mar 2026: 26.3)

Listed

Largest by share; two-brand strategy

Bupa HI

25.5

UK mutual-owned group

Close #2; strong in health services (dental, optical, aged care)

HCF

12.8

Not-for-profit

NSW-centric; aggressive on Gold product pricing

nib

9.8

Listed (ASX: NHF)

Growth-oriented; strong in international and NZ

HBF

7.9

Member-owned

WA-dominant; lowest 2026 premium rise (2.15%)

Defence Health

~2.0

Not-for-profit

Niche, restricted fund

Australian Unity, Teachers Health, GMHBA, CBHS, HIF

each ~1–3

Various

Regional or restricted funds

Key Competitors

CompetitorSegmentNote

Sonic Healthcare (IPN)

GP clinics

About 200+ centres and about 2,000 GPs, slightly larger than Medibank's ~168 clinics and ~1,750 GPs (AusDoc)

Bupa

GP and dental clinics

Expanding into GP clinics

Calvary, Silver Chain, others

Home and community care

Hospital-in-the-home and community nursing

Peer Comparison FY2025

MetricMedibank Private (fund entity)Bupa HIHCF

Insurance revenue FY2025 (AUD Bn)

7.958.704.14

Profit after tax FY2025 (AUD Mn)

574594191

Net margin (%)

7.26.84.6

Fund-level net investment income (AUD Mn)

1941710

Recent Developments

--

Company Snapshot

1976

Founded

Docklands, Australia

Headquarters

SWOT Analysis

Strengths

  • Market leadership with 26.3% resident PHI share (APRA, Mar 2026) and more than 6m people across the group.
  • Cost efficiency: HI expense ratio of 8.0% in FY2026, with about A$10m of productivity savings a year (A$132.4m cumulative).
  • Earnings resilience: group operating profit has grown every year from A$594.1m (FY2022) to A$813.5m (FY2026).
  • Capital strength: PCA coverage of 1.9x, no bank debt, and payout of 83% of underlying NPAT (FY2026).
  • Diversifying earnings: Medibank Health profit of A$100.7m (+31.3%), with community and acute care turning from a A$0.1m loss to A$10.1m profit.
  • Engagement moat: Live Better has 1.04m members, rewards claimed rose 48%, and Medibank says Live Better is a reason one in three people choose Medibank.

Weaknesses

  • Market share erosion: 26.5% (FY2025) to 26.3% (FY2026) on its own scorecard.
  • 2H26 policyholder growth of only 0.2%, with the lapse rate up to 5.8% in 2H26 vs 4.7% in 1H26.
  • Non-resident policy units −2.3% and gross margin −210bps to 34.8% (FY2026).
  • Growth relies on lower-tier products: Revenue Mix drag of −1.5% (FY2026), and it is expected to persist into FY2027.
  • JV hospital portfolio still loss-making (−A$6.6m share of losses).
  • Cyber legacy: A$35–46m a year in costs since FY2023, and the A$250m APRA capital overlay is still in place.

Opportunities

  • Medibank Health aspiration of more than A$200m profit by FY2030, about double FY2026.
  • Release of the A$250m APRA supervisory adjustment once remediation is complete, freeing capital for M&A or returns.
  • Primary-care network synergies from Myhealth plus Better Medical (168 clinics; 7m consults by the FY2028 milestone).
  • Hospital-in-the-home: each additional 3,000 enrolments saves about 21k bed days and about A$7.5m in benefit outlays (FY2026 presentation).
  • Non-resident worker segment: Medibank worker units +23% against +11% visa-grant growth.
  • Higher RBA cash rate sensitivity: +A$6.4m net investment income per 25bps.

Threats

  • OAIC civil penalty proceedings: up to A$2.22m per contravention, with 9.7m individuals affected.
  • Consumer class action now armed with the Deloitte reports after the March 2026 appeal refusal; shareholder class actions are also pending.
  • Competitor aggression and aggregator consolidation: the fourth quarter of FY2026 saw intensified competition.
  • Reversal of the FY2026 A$74.8m COVID utilisation benefit, which pressures FY2027 hospital claims.
  • Political and regulatory pressure on premiums: the 5.1% 2026 rise was above the 4.41% industry average.
  • Private-hospital sector distress forcing higher indexation and one-off funding (more than A$40m in FY2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 20251 April premium round (FY2025 average resident increase 3.48%)Revenue driver
May 2025Macquarie conference business update: growth broadly in line with market; expects Medibank-brand volume growthMomentum signal
28 Aug 2025FY2025 results: revenue +5.2% to A$8.604bn; HI operating profit +7.1% to A$741.5m; Medibank Health +27% to A$76.7m; underlying NPAT +8.5% to A$618.7m; final COVID give-back of A$228m (A$1.7bn total)Shares fell from near record highs after a strong year-to-date run
5 Sep 2025Board renewal: Fagan and Nicholls to retire; Hey and McIntyre nominatedGovernance refresh
Sep–Oct 2025FY2025 final dividend 10.2c paid 9 Oct 2025Capital return
Oct 2025Status update / investor slides (28 Oct 2025)Communication
Nov 2025Better Medical acquisition agreed (~A$159m)Primary-care scale; M&A at the top of the A$150–250m range
Nov 2025AGM; Hey and McIntyre electedBoard
Late 2025Weatherill retirement announced (effective 31 Dec 2025)Board
Late 2025 / Jan 2026Better Medical completion; network reaches 168 clinicsIntegration begins
6 Jan 2026Final director's notice for WeatherillAdmin
17 Feb 20262026 premium change announced (average 5.1% from 1 Apr 2026, per CHOICE; industry weighted average 4.41%)Above-industry increase; affordability scrutiny
19 Feb 2026HY2026: group operating profit +6.0% to A$381.7m; underlying NPAT −0.3% to A$297.8m; interim DPS 8.3c (+6.4%); net resident policyholders +38.3k (+1.9% over 12 months)Solid operations; lower investment income
23 Feb – 2 Mar 2026Director on-market purchases (McIntyre, Everingham, Hey)Insider confidence
20 Mar 2026Full Federal Court refuses leave to appeal on Deloitte-report privilege; reports to be produced in the consumer class actionRaises litigation risk
25 Mar 2026New substantial holder noticeRegister change
7–8 Apr 2026Unquoted securities issued and ceased (employee equity)Admin
30 Apr 2026Change in substantial holdingRegister
5 May 2026Macquarie conference update: resident policyholder growth of 22.4k in the nine months to Mar 2026 (+1.1% YTD), 25% higher than the prior-year period; no new material utilisation trends; competitors pursuing aggressive tacticsReassurance
15 May 2026FY2026 key dates; AGM set for 18 Nov 2026Calendar
29 May 2026APRA March-2026 statistics: 45.8% of the population with hospital coverIndustry backdrop
16 Jul 2026Change in substantial holdingRegister
20 Aug 2026FY2026 results: revenue +5.9% to A$9.115bn; group operating profit +6.7%; underlying NPAT +2.9% to A$636.8m; statutory NPAT +27.5% to A$638.7m; DPS 19.2c; FY2027 guidanceOperating profit about 1% below consensus; 2H policyholder growth soft (+0.2%)
2–3 Sep 2026Final dividend ex-date and record date—
16 Sep 2026Annual Report 2026, Corporate Governance Statement, first ASRS-aligned Sustainability ReportDisclosure
1 Oct 2026Medibank Group brand identity launched; 50th anniversary monthBrand
8 Oct 2026Final dividend 10.9c paidCapital return
18 Nov 2026 (upcoming)Annual General MeetingRemuneration vote; director elections

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Revenue by Segment (FY2024–FY2026): Premium revenue rose from AUD 7,903 Mn in FY2024 to AUD 8,585.1 Mn in FY2026.
MEDIBANK PRIVATE LTD — Revenue by Segment (FY2024–FY2026)
Series (AUD Mn)FY2024FY2025FY2026
Premium revenue7,9038,2118,585.1
Resident premium revenue07,908.88,267.9
Non-resident premium revenue0302.2317.2
Gross profit1,307.21,396.41,460
Management expenses614.9654.9690.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.